Newsletter | July 1, 2025

07.01.25 -- Exploring The Market For Closed-Loop Cell Therapy Production

FOCUS ON OUTSOURCING

Exploring The Market For Closed-Loop Cell Therapy Production

The second part of a discussion on closed-loop systems explores the CDMO and equipment landscape for scaling automated closed loop cell therapy manufacturing systems.

Rapid, Simple Aggregate Removal Of mAbs Using Competitive Binding

To ensure the safety, efficacy, and stability of monoclonal antibody therapies, it is crucial to understand the factors driving aggregation and implement effective strategies to mitigate its impact.

First-Time Outsourcing Guide: Biologics, pDNA, And mRNA Drug Products

Gain essential insights and practical guidance on outsourcing drug development and manufacturing, helping you make informed decisions and accelerate the success of your therapeutic initiatives.

Effective Technology Transfers For Mammalian-Derived Biologics

Technical transfers are one of the most critical, yet challenging steps in drug development; therefore, an effective strategy is essential to accelerate the translation of projects from bench to market.

The 5 Key Risks Of Failing To Select The Right CDMO Partner

For complex projects involving oral solid dosage (OSD) and sterile drug products, selecting the ideal CDMO can play a pivotal role in determining the success of a drug candidate.

Getting To The Heart Of CDMO Tech Transfer Excellence

Discover key factors that drive a seamless and efficient technology transfer. Learn how a culture of technical expertise, customer focus, and operational flexibility is crucial to CDMO success.

OUTSOURCING SOLUTIONS

Capacity Update October 2024: Large Molecule Drug Substance - Northway Biotech

Capacity Update January 2025: Large Molecule Development - KBI Biopharma

Capacity Update October 2024: Large Molecule Drug Substance - Pfizer CentreOne

Argonaut Quality Control Services - Argonaut Manufacturing Services

Connect With Bioprocess Online: